Bakırtaş M.Dal M.S.Yiğenoğlu T.N.Giden A.O.Serin I.Başcı S.Kalpakci Y.Korkmaz S.Ekinci O.Albayrak M.Basturk A.Ozatli D.Dogu M.H.Hacıbekiroglu T.Çakar M.K.Ulas T.Miskioglu M.Gulturk E.Eser B.Altuntas F.2024-07-222024-07-2220231120009Xhttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12314A multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least ≥ two lines of therapy. Patients’ treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 ± 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients. © 2023 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia (Italian Society of Chemotherapy).EnglishAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneHumansLenalidomideMiddle AgedMultiple MyelomaRetrospective StudiesTurkeybeta 2 microglobulindexamethasonehemoglobinixazomiblactate dehydrogenaselenalidomideproteasome inhibitorantineoplastic agentdexamethasoneixazomiblenalidomideabsolute neutrophil countadultadverse eventagedanemiaArticleatrial fibrillationbleedingclinical practiceconstipationcreatinine clearancedemographicsdiarrheadisease exacerbationdrug efficacydrug safetyECOG Performance Statusfemalefollow upglomerulus filtration ratehumanhypertensionInternational Staging Systemlaboratory testline of treatmentliver toxicitymajor clinical studymalemiddle agedmulticenter studymultiple cycle treatmentmultiple myelomaneutropeniaobservational studyoverall response rateplatelet countprogression free survivalrashretrospective studysurvivalthrombocytopeniatreatment responseTurkey (republic)clinical trialmultiple myelomaturkey (bird)Article10.1080/1120009X.2023.2208439